ACAD 241220 17.00C (ACAD241220C17000) Stock Options, News & Quotes

0.60
-1.00-62.50%

15min DelayClose Dec 13 16:00 ET

0.60High0.38Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Dec 11 15:06

News

$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· 1 min ago
ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Jaguar8

Nov 26 23:04

My Wednesday Watchlist. Trade the chart. Do not be impulsive. 11 stocks on watchlist today ran.

$HWH International (HWH.US)$ 13D 88.9%. China stock. Low float. SI 214%✅
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...

Jaguar8

Nov 26 15:13

NEWS

$ACADIA Pharmaceuticals (ACAD.US)$
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator.
The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential ...

Trytosaveabit

Nov 26 15:08

News

$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· 1 min ago
ACADIA Pharmaceuticals Inc - Saniona to Receive $28 Million Upfront Plus up to $582 Million in Milestones with exclusive licensing agreement with Saniona for San711

Trytosaveabit

Nov 5 15:06

News

$ACADIA Pharmaceuticals (ACAD.US)$ Reuters· just
ACADIA Pharmaceuticals Enters Into an Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million